|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Mood Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Depression | |||||
| Depressive Disorder | |||||
| Depressive Disorder, Major | |||||
| Disease | |||||
| Mood Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Behavioral Symptoms | |||||
| Mental Disorders | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| Wellbutrin XL | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Bupropion | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antidepressive Agents | |||||
| Antidepressive Agents, Second-Generation | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Queen's University | |||||